Presentation is loading. Please wait.

Presentation is loading. Please wait.

Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018  Jordi Remon, MD, Myung-Ju Ahn, MD, Nicolas Girard, MD, PhD, Melissa Johnson,

Published byÚΑἰσχύλος Πυλαρινός Modified over 4 years ago

Similar presentations

Presentation on theme: "Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018  Jordi Remon, MD, Myung-Ju Ahn, MD, Nicolas Girard, MD, PhD, Melissa Johnson,"— Presentation transcript:

1 Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018 
Jordi Remon, MD, Myung-Ju Ahn, MD, Nicolas Girard, MD, PhD, Melissa Johnson, MD, Dong-Wan Kim, MD, PhD, Gilberto Lopes, MD, Rathi N. Pillai, MD, Benjamin Solomon, M.B.B.S., Guillermo Villacampa, Qing Zhou, MD  Journal of Thoracic Oncology  Volume 14, Issue 7, Pages (July 2019) DOI: /j.jtho Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Acquired resistance mechanism after osimertinib treatment (n = 73). ∗Amplification events may be underrepresented in plasma analyses. Abbreviations: MET, MNNG HOS Transforming gene; amp, amplification; HER2, erb-b2 receptor tyrosine kinase gene; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alph gene; RET, ret proto-oncogene gene; ERC1, ELKS/RAB6-interacting/CAST family member 1 gene; CCNE1, cyclin E1 gene; FGFR3, fibroblast growth factor receptor 3 gene; TACC3, transforming acidic coiled-coil containing protein 3 gene; CCND2, cyclin D2 gene; CDK6, cyclin D6 gene. Reprinted from Papadimitrakopoulou et al.62 with permission from Annals of Oncology. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Acquired EGFR mutations after osimertinib treatment. Abbreviation: Ex20ins, exon 20 insertion. Reprinted from Papadimitrakopoulou et al.62 with permission from Annals of Oncology. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Acquired resistance mechanism to first-line osimertinib treatment (n = 91). ∗Resistance mechanism reported may overlap with another. #Two patients had de novo T790 mutations at baseline, with one of the patients acquiring C797S at progression. Abbreviations: HER2, erb-b2 receptor tyrosine kinase gene; SPTBN1, gene; ALK, gene; MET, MNNG HOS Transforming gene; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alph gene; mTOR, mechanistic target of rapamycin; BIM, synonym of BCL2L11 (i.e., BCL2 like 11); BCL2, BCL2, apoptosis regulato; CCND, cyclin D gene; CCNE1, cyclin E1 gene; CDK4, cyclin-dependent kinase 4 gene; CDK6, cyclin-dependent kinase 6 gene. Reprinted with permission from Ramalingam et al.63 with permission from Annals of Oncology. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018  Jordi Remon, MD, Myung-Ju Ahn, MD, Nicolas Girard, MD, PhD, Melissa Johnson,"

Similar presentations

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
Advances in Molecular Biology of Lung Disease

Advances in Molecular Biology of Lung Disease
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors  Alexa B. Schrock,

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors  Alexa B. Schrock,
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 
ERBB2-Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies  Jody C. Chuang, MD, PhD, Henning Stehr, PhD, Ying.

ERBB2-Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies  Jody C. Chuang, MD, PhD, Henning Stehr, PhD, Ying.
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Daniel Morgensztern, MD, Meghan J. Campo, MD, Suzanne E

Daniel Morgensztern, MD, Meghan J. Campo, MD, Suzanne E
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M

Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M
Ground glass opacities: Imaging, pathology, and gene mutations

Ground glass opacities: Imaging, pathology, and gene mutations
Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens  Judith N. Müller, PhD, Markus Falk, PhD, Jatin Talwar, MSc, Nicole.

Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens  Judith N. Müller, PhD, Markus Falk, PhD, Jatin Talwar, MSc, Nicole.
A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,
Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas?  Nicolas Girard, MD  Journal of Thoracic.

Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas?  Nicolas Girard, MD  Journal of Thoracic.
Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification  Justin.

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification  Justin.
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 
Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer  Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin,

Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer  Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin,
Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy  Sotirios Lakis,

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy  Sotirios Lakis,
Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication 

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication 

Similar presentations

Ads by Google